Literature DB >> 18325296

Update on the prophylaxis of migraine.

Markus Schürks1, Hans-Christoph Diener, Peter Goadsby.   

Abstract

Migraine prophylaxis is a stepwise procedure with lifestyle advice followed by consideration of medications. Patients should be advised to try to maintain a regular lifestyle, with regular sleep, meals, exercise, and management of stress, perhaps through relaxation techniques or other ways that are sensible for them. If this regimen does not adequately control their migraines, preventatives are indicated. Patients can choose between evidence-based nutraceuticals such as riboflavin, feverfew, butterbur, or coenzyme Q10, or more traditional pharmacotherapeutics. Medicine choices are somewhat limited by what is available in each country, but from the full range, the medicines of first choice are beta-adrenoceptor blockers, flunarizine, topiramate, and valproic acid. Beta-adrenoceptor blockers are particularly useful in patients also suffering from hypertension or tachycardia. Following recent studies, topiramate has become a first choice for episodic as well as chronic migraine. It is the only prophylactic drug that may lead to weight loss, but it is sometimes associated with adverse cognitive effects. Valproic acid and flunarizine also have very good prophylactic properties. However, valproic acid is often associated with adverse effects, and flunarizine is unavailable in many countries, including the United States. If sequential monotherapies are ineffective, combinations of first-line drugs should be tried before advancing to drugs of second choice, which are associated with more adverse effects or have less well-established prophylactic properties. Amitriptyline should be used carefully because of its anticholinergic effects, although it is useful in comorbid tension-type headache, depression, and sleep disorders. Methysergide is very effective, but it has been supplanted or even made unavailable in many countries because of its well-described association with retroperitoneal fibrosis. Pizotifen has a slightly better safety profile but is unavailable in the United States. Aspirin is particularly useful in patients needing platelet inhibitors for other medical conditions, but the risk of gastrointestinal bleeding must be considered. The prophylactic properties of magnesium, riboflavin, and coenzyme Q10 are low at best, but their lack of severe adverse effects makes them good treatment options. Magnesium may be particularly useful during pregnancy. Lisinopril and candesartan were shown to be effective in single trials and are preferable in patients with hypertension. Acupuncture may be another alternative; although controlled trials have failed to differentiate its effect from placebo, it is at least innocuous. Botulinum toxin A is not effective in the prophylaxis of episodic migraine.

Entities:  

Year:  2008        PMID: 18325296     DOI: 10.1007/s11940-008-0003-3

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  51 in total

1.  Lamotrigine versus placebo in the prophylaxis of migraine with and without aura.

Authors:  T J Steiner; L J Findley; A W Yuen
Journal:  Cephalalgia       Date:  1997-04       Impact factor: 6.292

2.  Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.

Authors:  S Evers; J Vollmer-Haase; S Schwaag; A Rahmann; I-W Husstedt; A Frese
Journal:  Cephalalgia       Date:  2004-10       Impact factor: 6.292

3.  Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial.

Authors:  J Schoenen; J Jacquy; M Lenaerts
Journal:  Neurology       Date:  1998-02       Impact factor: 9.910

4.  Naproxen sodium in the treatment of migraine.

Authors:  K M Welch
Journal:  Cephalalgia       Date:  1986       Impact factor: 6.292

5.  Efficacy of gabapentin in migraine prophylaxis.

Authors:  N T Mathew; A Rapoport; J Saper; L Magnus; J Klapper; N Ramadan; B Stacey; S Tepper
Journal:  Headache       Date:  2001-02       Impact factor: 5.887

6.  Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen D Silberstein; Richard B Lipton; David W Dodick; Frederick G Freitag; Nabih Ramadan; Ninan Mathew; Jan L Brandes; Marcelo Bigal; Joel Saper; Steven Ascher; Donna M Jordan; Steven J Greenberg; Joseph Hulihan
Journal:  Headache       Date:  2007-02       Impact factor: 5.887

7.  Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial.

Authors:  Hans-Christoph Diener; Kai Kronfeld; Gabriele Boewing; Margitta Lungenhausen; Christoph Maier; Albrecht Molsberger; Martin Tegenthoff; Hans-Joachim Trampisch; Michael Zenz; Rolf Meinert
Journal:  Lancet Neurol       Date:  2006-04       Impact factor: 44.182

8.  Efficacy of feverfew as prophylactic treatment of migraine.

Authors:  E S Johnson; N P Kadam; D M Hylands; P J Hylands
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-31

9.  Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.

Authors:  Sheena K Aurora; Marek Gawel; Jan L Brandes; Suriani Pokta; Amanda M Vandenburgh
Journal:  Headache       Date:  2007-04       Impact factor: 5.887

10.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

View more
  17 in total

1.  Drug-induced retroperitoneal fibrosis: short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology.

Authors:  C Alberti
Journal:  G Chir       Date:  2015 Jul-Aug

Review 2.  Acupuncture for the prevention of episodic migraine.

Authors:  Klaus Linde; Gianni Allais; Benno Brinkhaus; Yutong Fei; Michael Mehring; Emily A Vertosick; Andrew Vickers; Adrian R White
Journal:  Cochrane Database Syst Rev       Date:  2016-06-28

Review 3.  OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.

Authors:  James E Frampton
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546

Review 4.  Non-pharmacological management of migraine during pregnancy.

Authors:  Gisella Airola; Gianni Allais; Ilaria Castagnoli Gabellari; Sara Rolando; Ornella Mana; Chiara Benedetto
Journal:  Neurol Sci       Date:  2010-06       Impact factor: 3.307

Review 5.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

6.  Topiramate in pregnancy and breastfeeding.

Authors:  Salvatore Gentile
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

7.  Targeting the central projection of the dural trigeminovascular system for migraine prophylaxis.

Authors:  Simon Akerman; Marcela Romero-Reyes
Journal:  J Cereb Blood Flow Metab       Date:  2017-09-08       Impact factor: 6.200

8.  Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial.

Authors:  Anjali Lepcha; Sophia Amalanathan; Ann Mary Augustine; Amit Kumar Tyagi; Achamma Balraj
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-29       Impact factor: 2.503

Review 9.  Recent Approaches and Development of Acupuncture on Chronic Daily Headache.

Authors:  Yinglu Liu; Shengyuan Yu
Journal:  Curr Pain Headache Rep       Date:  2016-01

Review 10.  Managing Migraine During Pregnancy and Lactation.

Authors:  Rebecca Erwin Wells; Dana P Turner; Michelle Lee; Laura Bishop; Lauren Strauss
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.